Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome
Spliceosome mutations occur in approximately 50% of patients with myelodysplastic syndromes. Here, the authors show that tumour cells harbouring theS34F mutation in the U2AFspliceosome gene is sensitive to compounds that further perturb the spliceosome.
Guardado en:
Autores principales: | Cara Lunn Shirai, Brian S. White, Manorama Tripathi, Roberto Tapia, James N. Ley, Matthew Ndonwi, Sanghyun Kim, Jin Shao, Alexa Carver, Borja Saez, Robert S. Fulton, Catrina Fronick, Michelle O’Laughlin, Chandraiah Lagisetti, Thomas R. Webb, Timothy A. Graubert, Matthew J. Walter |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/58561889db084efca98a8125161aeb78 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency
por: George B. Kyei, et al.
Publicado: (2018) -
Evolution of the Early Spliceosomal Complex—From Constitutive to Regulated Splicing
por: Sonia Borao, et al.
Publicado: (2021) -
Therapeutic activity of modified U1 core spliceosomal particles
por: Malgorzata Ewa Rogalska, et al.
Publicado: (2016) -
Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly
por: Pravin Kumar Ankush Jagtap, et al.
Publicado: (2020) -
Arabidopsis Spliceosome Factor SmD3 Modulates Immunity to Pseudomonas syringae Infection
por: Anna Golisz, et al.
Publicado: (2021)